Gautam Borthakur

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 76 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00192-7

N/A

5.0DataRank · unranked

178 citations

Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado +13 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Clinical Infectious Diseases(2020)10.1093/cid/ciaa358

N/A

3.1DataRank · unranked

77 citations

David McCue, Sebastian Wurster, Nathan P. Wiederhold, Marina Konopleva, Tapan M. Kadia +18 more

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Blood Cancer Journal(2022)10.1038/s41408-021-00604-2

N/A

2.5DataRank · unranked

95 citations

Koichi Takahashi, Naval Daver, Abhishek Maiti, Gautam Borthakur, Sanam Loghavi +14 more

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

American Journal of Hematology(2023)10.1002/ajh.27070

N/A

1.6DataRank · unranked

48 citations

Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S. Chien +19 more

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01476-8

N/A

1.3DataRank · unranked

51 citations

Muharrem Müftüoğlu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban‐Bravo +22 more

Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma

Cancer(2020)10.1002/cncr.33188

N/A

1.2DataRank · unranked

37 citations

Giovanni Martinelli, Emmanuel Raffoux, Patrice Chevallier, Jörg Chromik, Andrew Lithio +6 more

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2024)10.1182/bloodadvances.2023012231

N/A

0.940DataRank · unranked

34 citations

Elias Jabbour, Nitin Jain, Jayastu Senapati, Lewis Nasr, Fadi Haddad +18 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Nature Cancer(2024)10.1038/s43018-024-00811-3

N/A

0.878DataRank · unranked

37 citations

Divij Verma, Natalia Baran, Tushar D. Bhagat, Anna Skwarska, Alessia Lodi +42 more

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

Leukemia & Lymphoma(2008)10.1080/10428190701882146

N/A

0.697DataRank · unranked

103 citations

Samih El Ahdab, Farhad Ravandi, Stefan Faderl, Alessandra Ferrajoli, Beth Newman +3 more

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Blood Cancer Journal(2021)10.1038/s41408-021-00557-6

N/A

0.692DataRank · unranked

100 citations

Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning +16 more

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Cancer(2021)10.1002/cncr.33814

N/A

0.593DataRank · unranked

51 citations

Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias Jabbour, Caitlin R. Rausch +18 more

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial

The Lancet Haematology(2024)10.1016/s2352-3026(24)00250-3

N/A

0.561DataRank · unranked

17 citations

Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C. Issa +14 more

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

Cancer(2021)10.1002/cncr.33745

N/A

0.524DataRank · unranked

32 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Faezeh Darbaniyan, Elias Jabbour, Carlos E. Bueso‐Ramos +13 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0.483DataRank · unranked

24 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Advances(2023)10.1182/bloodadvances.2022009632

N/A

0.483DataRank · unranked

24 citations

Faustine Ong, Farhad Ravandi, Graciela M. Nogueras‐González, Tapan M. Kadia, Naval Daver +15 more

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

American Journal of Hematology(2023)10.1002/ajh.26997

N/A

0.442DataRank · unranked

18 citations

Hagop M. Kantarjian, Naszrin Arani, Uday Popat, Álex Bataller, Koji Sasaki +19 more

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7512

N/A

0.360DataRank · unranked

10 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Yesid Alvarado, Tapan M. Kadia +14 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519

N/A

0.330DataRank · unranked

8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

Research Square(2023)10.21203/rs.3.rs-2518774/v1

N/A

0.312DataRank · unranked

7 citations

Courtney D. DiNardo, Tushar D. Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena +38 more

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01724-z

N/A

0.254DataRank · unranked

4 citations

Wenbin Xiao, Gautam Borthakur, Le Xuan Truong Nguyen, Melissa Valerio, Avanthika Venkatachalam +11 more

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

American Journal of Hematology(2025)10.1002/ajh.70046

N/A

0.245DataRank · unranked

4 citations

Sanam Loghavi, Alexandre Bazinet, Álex Bataller, Ian Bouligny, Naval Daver +15 more

Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy

Haematologica(2024)10.3324/haematol.2024.285448

N/A

0.241DataRank · unranked

4 citations

Erika Borlenghi, Mark R. Litzow, John C. Byrd, Cristina Papayannidis, Cristina Tecchio +34 more

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Haematologica(2025)10.3324/haematol.2024.286559

N/A

0.165DataRank · unranked

2 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado +19 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Blood Neoplasia(2025)10.1016/j.bneo.2025.100145

N/A

0.104DataRank · unranked

1 citations

Wei‐Ying Jen, Guillermo Montalban‐Bravo, Xuemei Wang, Sanam Loghavi, Sravanthi Lavu +15 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood(2024)10.1182/blood-2024-207413

N/A

0.104DataRank · unranked

1 citations

Jennifer Marvin‐Peek, Marina Konopleva, Gautam Borthakur, Naval Daver, Hussein A. Abbas +21 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood(2023)10.1182/blood-2023-190400

N/A

0DataRank · unranked

1 citations

Zongrui Li, Abhishek Maiti, Tomoyuki Tanaka, Hidetaka Uryu, Ken Furudate +21 more

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Blood(2023)10.1182/blood-2023-182841

N/A

0DataRank · unranked

0 citations

Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour +12 more

Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007981

N/A

0DataRank · unranked

30 citations

Akriti Agrawal, Gautam Borthakur, Venkata Lokesh Battula, Abhishek Maiti, Adishwar Rao

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Haematologica(2024)10.3324/haematol.2023.284078

N/A

0DataRank · unranked

15 citations

Lucia Masárová, Naveen Pemmaraju, Sharon Bledsoe, Naval Daver, Elias Jabbour +19 more

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood(2024)10.1182/blood-2024-203706

N/A

0DataRank · unranked

5 citations

Jayastu Senapati, Sanam Loghavi, Patrick K. Reville, Bofei Wang, Tapan M. Kadia +21 more

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Blood(2024)10.1182/blood-2024-211599

N/A

0DataRank · unranked

3 citations

H. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo +13 more

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood(2024)10.1182/blood-2024-208890

N/A

0DataRank · unranked

1 citations

Kelly S. Chien, Sanam Loghavi, Rashmi Kanagal‐Shamanna, Anuya Natu, Mark E. Gurney +22 more

Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML

Research Square(2024)10.21203/rs.3.rs-4954060/v1

N/A

0DataRank · unranked

0 citations

Wenbin Xiao, Gautam Borthakur, Le Xuan Truong Nguyen, Melissa Valerio, Avanthika Venkatachalam +11 more

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood(2024)10.1182/blood-2024-210779

N/A

0DataRank · unranked

0 citations

Hussein A. Abbas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo +19 more

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Blood(2024)10.1182/blood-2024-202414

N/A

0DataRank · unranked

0 citations

H. Kantarjian, Wei‐Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti +14 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70171

N/A

0DataRank · unranked

3 citations

Guojun Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Alexandre Bazinet +20 more

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica(2025)10.3324/haematol.2025.288553

N/A

0DataRank · unranked

2 citations

Sanam Loghavi, Musa Yılmaz, Omer Karrar, Kunhwa Kim, Courtney D. DiNardo +15 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0229

N/A

0DataRank · unranked

15 citations

Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi +21 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Blood(2020)10.1182/blood.2019002922

N/A

0DataRank · unranked

73 citations

Warren Fiskus, Christopher P. Mill, Dimuthu Perera, Taghi Manshouri, Bernardo H Lara +18 more

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32623

N/A

0DataRank · unranked

21 citations

Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva +11 more

Germline DNMT3A mutation in familial acute myeloid leukaemia

Epigenetics(2020)10.1080/15592294.2020.1809871

N/A

0DataRank · unranked

10 citations

Hannah C. Beird, Marcos R. Estecio, Swanand Hardikar, Koichi Takahashi, Sarah A. Bannon +12 more

Long‐term results of frontline dasatinib in chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32627

N/A

0DataRank · unranked

34 citations

Jörge E. Cortes, Keyur P. Patel, Lucia Masárová, Gautam Borthakur, Farhad Ravandi +14 more

Clinical value of event-free survival in acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001150

N/A

0DataRank · unranked

7 citations

Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Konopleva +16 more

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

American Journal of Hematology(2020)10.1002/ajh.25991

N/A

0DataRank · unranked

6 citations

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia +13 more

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.04.283598

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Elias Jabbour, Carlos E. Bueso‐Ramos, Yue Wei +14 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0DataRank · unranked

126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Blood Advances(2021)10.1182/bloodadvances.2020003934

N/A

0DataRank · unranked

48 citations

Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Tapan M. Kadia +7 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z

N/A

0DataRank · unranked

45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia(2021)10.1038/s41375-021-01240-2

N/A

0DataRank · unranked

31 citations

Danielle Hammond, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J. Short +15 more

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

Blood Cancer Journal(2021)10.1038/s41408-021-00446-y

N/A

0DataRank · unranked

10 citations

Guillermo Montalban‐Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour +26 more

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Cancer(2021)10.1002/cncr.33409

N/A

0DataRank · unranked

10 citations

Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Xuemei Wang, Elias Jabbour +16 more

Contemporary outcomes for adults with AML requiring ICU admission.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7025

N/A

0DataRank · unranked

4 citations

Koji Sasaki, Alexis Geppner, Fadi Haddad, Shehab Mohamed, Daniel Rivera +15 more

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Advances(2022)10.1182/bloodadvances.2022008316

N/A

0DataRank · unranked

56 citations

Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia +20 more

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01229-z

N/A

0DataRank · unranked

32 citations

Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron +18 more

Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL

Leukemia(2022)10.1038/s41375-022-01516-1

N/A

0DataRank · unranked

32 citations

Ya‐Ling Yang, Seemana Bhattacharya, Priyanka Sharma, Huaxian Ma, Hong Mu +11 more

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy

Haematologica(2022)10.3324/haematol.2022.280884

N/A

0DataRank · unranked

28 citations

Guopan Yu, Hongying Zhang, Mahesh Basyal, Charlie Ly, Bin Yuan +10 more

Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia

Experimental Hematology and Oncology(2022)10.1186/s40164-022-00309-7

N/A

0DataRank · unranked

10 citations

Elliana Young, Feng Chun, Suyu Liu, Fengyi Jin, Laila Noor +5 more

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Blood Advances(2022)10.1182/bloodadvances.2021006689

N/A

0DataRank · unranked

1 citations

Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short +6 more

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

Leukemia Research(2022)10.1016/j.leukres.2022.106884

N/A

0DataRank · unranked

1 citations

Alexandre Bazinet, Sanam Loghavi, Marina Konopleva, Kapil N. Bhalla, Naval Daver +10 more

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

Molecular Cancer Research(2023)10.1158/1541-7786.mcr-22-0343

N/A

0DataRank · unranked

16 citations

Sujan Piya, Huaxian Ma, Priyanka Sharma, Qi Zhang, Natalia Baran +10 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1429

N/A

0DataRank · unranked

23 citations

Warren Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia‐Manero +19 more

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

Cancer(2023)10.1002/cncr.34728

N/A

0DataRank · unranked

20 citations

Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan +12 more

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Leukemia(2023)10.1038/s41375-023-02108-3

N/A

0DataRank · unranked

11 citations

Warren Fiskus, Tapan M. Kadia, Christopher P. Mill, Koji Sasaki, Naval Daver +13 more

TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax

Leukemia(2023)10.1038/s41375-023-02086-6

N/A

0DataRank · unranked

4 citations

Appalaraju Jaggupilli, Stanley Ly, Bin Yuan, Fouad El-Dana, Venkatesh L. Hegde +13 more